Comparing the use and discontinuation of antipsychotics in clinical practice: An observational study

Journal of Clinical Psychiatry

Volumn 69, Issue 2, 2008, Pages 240-245

  Taylor, Mark ^a   Shajahan, Polash ^b   Lawrie, Stephen M ^c  

^a Springpark Centre   (United Kingdom)

^b NHS Lanarkshire   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; COMPARATIVE STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MOOD DISORDER; PERSONALITY DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 41549164832     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0210     Document Type: Article

References (22)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
2. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of 2230 patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow up study. BMJ 2006;333:224
3. Davis J, Chen N, Glick I. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
4. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
5. National Institute for Clinical Excellence. Guidance on the Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London, England: NICE; 2002
6. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622
7. Scottish Public Health Observatory. Comparative Health Profiles. Available at: http://www.scotpho.org.uk/web/site/home/comparativehealth/ profiles. Accessibility verified August 13, 2007
8. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO; 1992
9. Peres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head to head comparison studies of second generation antipsychotics. Am J Psychiatry 2006;163:185-194
10. NHS National Services Scotland. Information Services Division (ISD) Scotland. Available at: http://www.isdscotland.org. Accessibility verified August 13, 2007
11. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
12. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomised trials. Schizophr Res 2002;56:1-10
13. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-244
14. British National Formulary, 2007. Available at: http://bnf.org/bnf. Accessibility verified August 13, 2007
15. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208
16. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79:145-155
17. Lowe-Ponsford F, Baldwin D. Off-label prescribing by psychiatrists. Psychiatr Bull 2000;24:415-417
18. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
19. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-1290
20. Paton C, Lelliot P, Harrington M, et al. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003;17:223-229
21. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-329
22. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-706